Search Follow us

Imugene (IMU)

Business description

Imugene is an immune oncology company developing HER-Vaxx, a proprietary HER2 +ve cancer vaccine. A Ph Ib dose study is planned in gastric cancer starting in mid-2016 with a direct Ph II follow-on study in 68 patients.

Termination of coverage

Update | Pharmaceutical & healthcare | 21/09/2016

Edison Investment Research is terminating coverage on Imugene (IMU). Please note you should no longer rely on any previous research or estimates for this company. All forecasts should now be considered redundant.

Edison's research is freely available. We will never ask for your credit card details and you do not need to register. By downloading this research you are agreeing to our terms and conditions, which you can read in full here.

Company news


Thu, 27 Aug 2015 07:40:18 GMT


Wed, 28 Oct 2015 04:00:21 GMT


Wed, 07 Feb 2018 02:03:45 GMT


Fri, 01 Sep 2017 07:11:38 GMT


Sun, 11 Feb 2018 21:56:15 GMT